ICU · GI/Nutrition
Hepatic encephalopathy and acute liver failure
Also known as Hepatic encephalopathy (HE) · Acute liver failure (ALF) · West Haven classification · Acute-on-chronic liver failure (ACLF) · King's College Criteria
Hepatic encephalopathy is a reversible spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, classified by the West Haven system (Grade I-IV). Pathophysiology centres on ammonia-induced astrocyte swelling and systemic inflammation. Precipitating factors include infection, GI bleed, constipation, sedatives, and electrolyte disturbance. Management: lactulose (first-line), rifaximin (add-on), treat precipitant, avoid sedatives, protein restriction NOT recommended. Acute liver failure (ALF) is a separate entity with different management priorities: N-acetylcysteine (improves survival in non-acetaminophen ALF), intracranial pressure management, and liver transplant listing using King's College Criteria.
On this page & tools
Your progress
Saved locally on this device.
Target exams
Red flags
Definition and classification
Hepatic encephalopathy (West Haven classification)
West Haven HE grading (click each)
Somnolent — overt
Somnolent but arousable, gross disorientation, bizarre behaviour, marked asterixis, muscular rigidity, hyperreflexia. Intubate for airway protection.
Type of HE
| Type | Description | Example |
|---|---|---|
| Type A | Acute liver failure-related | Paracetamol overdose, viral hepatitis |
| Type B | Bypass-related (no intrinsic liver disease) | Portosystemic shunt |
| Type C | Cirrhosis-related (most common) | Precipitant-induced or recurrent |
Pathophysiology
Ammonia hypothesis: Gut bacteria produce ammonia from dietary protein and urea. Ammonia bypasses hepatic clearance (portosystemic shunting or hepatocyte dysfunction) and crosses the blood-brain barrier.[2]
- Ammonia enters astrocytes → metabolised to glutamine (via glutamine synthetase)
- Glutamine accumulation → astrocyte swelling → cerebral oedema
- Astrocyte dysfunction impairs neuron-astrocyte metabolic coupling and neurotransmitter recycling
- Systemic inflammation (from infection, GI translocation) synergises with ammonia to worsen neuroinflammation
- In acute liver failure, rapid ammonia rise causes cytotoxic cerebral oedema → raised ICP → herniation (the most common cause of death in ALF) [1]
Competing pathophysiological hypotheses
Ammonia hypothesis
Best supported
- Gut bacteria generate ammonia from dietary protein and urea; ammonia bypasses hepatic clearance (portosystemic shunting or hepatocyte loss)
- Ammonia crosses the BBB → astrocyte → glutamine synthetase → glutamine accumulation
- Glutamine is osmotically active → astrocyte swelling → cytotoxic oedema and impaired neurotransmitter recycling
- Arterial ammonia >150-200 umol/L correlates with cerebral herniation risk in acute liver failure
- Underpins therapy: lactulose (ion-traps ammonia), rifaximin (cuts bacterial ammonia production), LOLA (substrate for urea cycle)
GABA / benzodiazepine
Explains flumazenil response
- Increased GABAergic inhibitory tone in HE
- Endogenous benzodiazepine-like substances (gut-derived) accumulate in brain
- Altered astrocytic GABA transporter and receptor expression
- Explains why flumazenil (benzodiazepine receptor antagonist) transiently improves ~25% of patients
- Does NOT support routine flumazenil — response is short-lived and inconsistent; a diagnostic trial only
Inflammation / neuroinflammation
Synergistic amplifier
- Systemic inflammation (infection, sepsis) increases BBB permeability to ammonia
- Microglial activation releases IL-1b, IL-6, TNF-a — amplifies neurotoxicity
- Explains why infection is the #1 precipitant — inflammation lowers the ammonia threshold for encephalopathy
- Neutrophil dysfunction in cirrhosis contributes to cerebral oxidative stress
- Ammonia + inflammation act synergistically — neither alone fully predicts severity
Other contributors
Adjunct mechanisms
- Manganese deposition in basal ganglia (chronic portosystemic shunting) — extrapyramidal signs, T1 hyperintensity on MRI
- Reduced branched-chain / aromatic amino acid ratio → false neurotransmitters (octopamine)
- Impaired astrocyte-neuron metabolic coupling and glutamate uptake
- Cerebral energy metabolism impairment
Precipitating factors
Common precipitants
Find and treat ALL
- Infection (#1 — spontaneous bacterial peritonitis, pneumonia, UTI)
- GI bleed (protein load from digested blood increases ammonia)
- Constipation (increased ammonia absorption)
- Sedatives (benzodiazepines — worsen GABAergic tone)
- Hypokalaemia (increases renal ammoniagenesis)
- Hyponatraemia
- Dehydration / diuretic overdiuresis
- TIPS procedure (increases portosystemic shunting)
- Alcohol withdrawal
Investigation workup
For every HE presentation
- Blood cultures + urine culture + ascitic tap
- FBC, U&E (K, Na), LFTs, coagulation (INR)
- Serum ammonia (not always needed but helps in diagnostic uncertainty)
- CT brain (exclude structural lesion, haemorrhage)
- Glucose (hypoglycaemia mimics HE)
- Drug screen (if suspected)
- Review medications (stop benzodiazepines, opioids)
Diagnosis of hepatic encephalopathy
HE is a clinical diagnosis of exclusion — there is no single confirmatory test. The diagnosis requires: (1) underlying liver disease or portosystemic shunt, (2) neuropsychiatric features consistent with HE, and (3) exclusion of alternative causes of altered mental status. [1]
Diagnostic workup for suspected HE
Bedside clinical assessment
Grade mental state by West Haven. Elicit asterixis (flapping tremor — patient holds arms outstretched with wrists dorsiflexed for 30 seconds; present in Grade II-III, absent in coma/Grade IV). Test constructional apraxia (cannot draw a five-pointed star — sensitive for covert HE). Look hard for a precipitant: fever, ascites, melaena, dehydration, recent TIPS, new sedative.
Laboratory evaluation
FBC, U&E, LFTs, coagulation (INR), glucose (hypoglycaemia mimics HE), magnesium, CRP, ammonia (arterial preferred over venous). Send blood cultures, urine culture, and perform a diagnostic ascitic tap — paracentesis is MANDATORY in any cirrhotic with ascites and HE to exclude SBP (neutrophils >250/mm3). SBP can be culture-negative neutrocytic ascites.
Neuroimaging
CT brain to exclude structural lesion — subdural haematoma (falls are common in cirrhosis), intracranial haemorrhage, or infarct. MRI may show T1 hyperintensity in basal ganglia (manganese deposition) in chronic portosystemic shunting. Imaging is NORMAL in HE itself — the scan is to exclude mimics, not to confirm.
Electroencephalogram (EEG)
Characteristic but non-specific finding is **triphasic waves** (5 Hz, high-amplitude, frontally predominant), seen in Grade II-IV HE. Background rhythm slows (alpha → theta → delta) as HE progresses. Triphasic waves are NOT pathognomonic — also seen in uraemia, hyponatraemia, hypoxic-ischaemic encephalopathy, lithium toxicity. Main ICU role: exclude non-convulsive status epilepticus in the unexplained comatose cirrhotic.
Psychometric testing for covert (Grade I) HE
Psychometric Hepatic Encephalopathy Score (PHES) — number connection tests, line tracing, serial dotting, digit symbol. Inhibitory control test and the Stroop smartphone app are validated screening tools. Covert HE affects 50-80% of cirrhotics, predicts overt HE, impairs driving safety — important to identify even when the bedside exam looks normal.
Exclude the mimics
Differential of altered mental status in cirrhosis: hypoglycaemia, hyponatraemia, sepsis/septic encephalopathy, alcohol intoxication or withdrawal, Wernicke encephalopathy (GIVE THIAMINE), intracranial bleed, drug toxicity (including unrecognised benzodiazepine/opioid), uraemia, CO2 narcosis, subdural haematoma. Treat empirically for reversible causes while the workup proceeds.
Asterixis (flapping tremor)
Bedside hallmark
- Patient holds arms outstretched, wrists dorsiflexed, fingers spread for 30 seconds
- Abrupt loss of sustained wrist posture produces a flapping motion
- Present in Grade II-III HE; ABSENT in Grade I (too subtle) and Grade IV (too deep)
- NOT specific to HE — also seen in uraemia, hypercapnia, severe cardiac failure, drug withdrawal
- Absence does NOT exclude HE; presence does NOT confirm it
EEG triphasic waves
Supportive, not specific
- Bilateral, symmetrical, frontally predominant 5 Hz waves with three-phase morphology
- Appear in Grade II-IV HE
- Also seen in uraemic encephalopathy, hyponatraemia, hypoxic-ischaemic encephalopathy, lithium toxicity
- Background rhythm slows (alpha → theta → delta) as HE progresses
- Main value: exclude non-convulsive status epilepticus in the unexplained comatose cirrhotic
Ammonia level
Trend, do not diagnose
- Arterial preferred over venous (muscle uptake lowers venous)
- Sample on ice, processed promptly (falsely elevated if delayed)
- Correlates poorly between patients, better within an individual over time
- Arterial ammonia >200 umol/L in ALF predicts intracranial hypertension
- A normal ammonia does NOT exclude HE — the diagnosis remains clinical
Management of hepatic encephalopathy
HE management protocol
Identify and treat the precipitant
This is the MOST IMPORTANT step. Treat infection (antibiotics), stop GI bleed (endoscopy), correct hypokalaemia, treat constipation (lactulose serves dual purpose), stop sedatives. Without treating the precipitant, all other therapies will fail.
Lactulose — first-line
15-30 mL orally (or via NG/PR) 2-4 times daily. Titrate to achieve 2-3 soft bowel movements per day. Mechanism: converts NH3 to NH4+ (non-absorbable) in the colon, traps ammonia in stool, and promotes excretion via catharsis. Overdose causes diarrhoea → dehydration → worsens HE. Monitor hydration.
Rifaximin — add-on for recurrent HE
550 mg orally BD. Non-absorbable antibiotic that reduces gut ammonia-producing bacteria. Used IN ADDITION to lactulose for patients with recurrent HE (≥2 episodes). Cochrane review: reduces mortality and HE recurrence. Not a replacement for lactulose.
Avoid hepatotoxic and CNS-depressant drugs
STOP benzodiazepines (worsen HE via GABAergic tone). STOP opioids (constipating, CNS depression). Use paracetamol for analgesia (safe in low doses). Avoid NSAIDs (renal risk, bleeding risk). Metabolism of many drugs is impaired — adjust doses.
Nutrition — do NOT restrict protein
Target protein intake 1.2-1.5 g/kg/day. Protein restriction is OUTDATED and worsens outcomes (catabolism, sarcopenia, immune dysfunction). Vegetable protein may be slightly better tolerated than animal protein. Enteral nutrition preferred.
Airway protection (Grade III-IV)
Intubate for airway protection if Grade III (somnolent) or Grade IV (comatose). Risk of aspiration pneumonia. Mechanical ventilation with standard settings. Avoid PEEP >10 if portal hypertension (reduces venous return).
Consider alternative therapies
L-ornithine L-aspartate (LOLA) — enhances ammonia metabolism (evidence emerging). Branched-chain amino acids — modest benefit. Zinc supplementation (if deficient — cofactor for ornithine transcarbamylase). Polyethylene glycol (PEG) — may be faster than lactulose for acute HE resolution.
Hepatorenal overlap and refractory HE
Hepatorenal syndrome (HRS-AKI) complicating HE
HE and AKI frequently coexist in decompensated cirrhosis and share precipitants. Recognising the overlap matters because some HE therapies (lactulose, diuretics) can themselves precipitate or worsen AKI. [1]
Why HE and AKI coexist
A vicious cycle
- Sepsis / SBP precipitates BOTH HE and HRS — type 1 HRS classically follows bacterial infection
- Diuretic overdiuresis → hypovolaemia → AKI AND worsens HE via dehydration and electrolyte disturbance
- Lactulose overdose → diarrhoea → hypovolaemia → AKI (an iatrogenic cause)
- Hypokalaemia drives BOTH renal ammoniagenesis (HE) and tubular injury (AKI)
- Type 1 HRS: rapid AKI over days, doubling of creatinine, very high mortality without vasoconstrictor therapy or transplant
HRS-AKI management (ICA criteria)
Adjunct to HE therapy
- Diagnose HRS-AKI: cirrhosis + ascites + AKI (rise in Cr ≥26 umol/L in 48h or ≥50% within 7d) + no response to 2 days of albumin + no shock / nephrotoxin / structural kidney disease
- Stop ALL diuretics and nephrotoxins (NSAIDs, ACE inhibitors, ARBs, iodinated contrast)
- Volume challenge first: 20% albumin 1 g/kg/day (max 100 g/day) for 2 days before labelling HRS
- If no response: terlipressin (or noradrenaline infusion) + albumin — splanchnic vasoconstriction
- CRRT if refractory or as bridge to transplant; continuous modality preferred (haemodynamic stability, no rapid solute shift to worsen cerebral oedema)
- Do NOT use prophylactic FFP to correct INR — INR is a liver-function marker, not a bleeding-risk marker in stable ALF
Refractory or recurrent HE — escalating therapy
When standard lactulose ± rifaximin fails
Confirm adherence and dosing
Lactulose must be titrated to 2-3 soft stools/day. Many refractory cases are simply under-dosed (no catharsis) or over-dosed (diarrhoea worsens HE via dehydration). Check the NG/PR route is patent in intubated patients. Confirm rifaximin 550 mg BD is actually being administered.
Re-examine for a missed precipitant
Repeat the septic screen (SBP can be culture-negative neutrocytic ascites; consider fungal infection or occult abscess). Re-image for a portosystemic shunt (a large spontaneous or iatrogenic shunt may need embolisation). Review the drug chart — unrecognised sedative, opioid, or benzodiazepine co-prescription is common.
Escalate ammonia-lowering therapy
Add LOLA (L-ornithine L-aspartate) IV — provides substrate for the urea cycle and glutamine synthesis. Add zinc (deficiency is common in cirrhosis; zinc is a cofactor for ornithine transcarbamylase). Consider polyethylene glycol (PEG) for an acute flare — the HELP study showed faster resolution than lactulose.
Consider a flumazenil trial
Flumazenil (benzodiazepine receptor antagonist) 1 mg IV produces transient improvement in ~25% of HE patients (those with endogenous benzodiazepine-like activity). This is diagnostic rather than therapeutic — the short half-life means no sustained role. AVOID if tricyclic antidepressant co-ingestion or chronic benzodiazepine dependence (seizure risk).
Embolise a large portosystemic shunt
In patients with recurrent or refractory HE and a demonstrable large spontaneous shunt on CT/MRI angiography, radiological embolisation can reduce portosystemic ammonia delivery and improve HE. Consider in specialist centres for selected patients.
Liver transplant assessment
Recurrent overt HE reflects decompensated cirrhosis — refer for transplant evaluation. MELD-Na drives listing priority; HE itself is NOT in the MELD score but predicts waitlist mortality, and post-transplant cognitive recovery is usually (but not always) complete.
Key trial — rifaximin for prevention of recurrent HE
Bass et al. 2010 (NEJM) — rifaximin to prevent recurrent hepatic encephalopathy (PMID 20375586)
Study design
Multicentre, randomised, double-blind, placebo-controlled trial — 299 cirrhotic patients with at least 2 episodes of overt HE in the previous 6 months, all in remission at enrolment
Intervention
Rifaximin 550 mg orally twice daily vs placebo for 6 months, ADDED to baseline therapy (91% were already on concomitant lactulose)
Primary outcome
Time to first breakthrough overt HE episode over 6 months
Key result
Rifaximin reduced breakthrough HE by 58% (HR 0.42, 95% CI 0.28-0.64; p<0.001) and reduced HE-related hospitalisation by about 50% (HR 0.50, 95% CI 0.29-0.87; p=0.01). No increase in adverse events or Clostridioides difficile infection.
Caveats
Trial was powered for breakthrough HE, NOT mortality; almost all patients remained on lactulose, so it does NOT test rifaximin monotherapy. Benefit is best established for secondary prevention (at least 2 prior episodes), not first episode.
Bottom line
Rifaximin 550 mg BD, ADDED to lactulose, reduces recurrent overt HE and HE-related admissions. An ADD-ON, never a replacement for lactulose.
Special situations: TIPS and post-liver-transplant
TIPS-related hepatic encephalopathy
Transjugular intrahepatic portosystemic shunt (TIPS) acutely increases portosystemic shunting — gut ammonia and other neurotoxins now bypass the liver directly. New or worsening HE occurs in roughly 20-50% of patients post-TIPS, typically within the first month. Most episodes are self-limiting and resolve within 3 months as the body adapts (and as muscle glutamine synthetase partially compensates), but a minority are refractory. [1]
Risk factors for post-TIPS HE
Pre-TIPS assessment
- Prior history of HE (the strongest predictor)
- Age over 65 years
- Child-Pugh score above 10 or MELD above 18
- Indication other than variceal bleeding — ascites or refractory ascites carry higher risk
- Large stent diameter (10 mm vs 8 mm) — consider a smaller covered stent
- Muscle depletion or sarcopenia (loss of extra-hepatic ammonia clearance in muscle)
Management of post-TIPS HE
Often self-limiting
- Reassure — most episodes resolve within 3 months as the body adapts
- Standard first-line: lactulose titrated to 2-3 soft stools/day
- Add rifaximin 550 mg BD if recurrent or persistent — prophylactic rifaximin is reasonable in high-risk patients
- Refractory cases: radiological stent diameter reduction or flow-occlusion (multidisciplinary, transplant centre)
- Protein restriction is NOT appropriate — it worsens sarcopenia, the key risk factor
Post-liver-transplant neurocognitive disorders
After transplant, persistent or new HE-like syndromes may arise, and the differential shifts toward drug and procedural causes. Recognising these is essential because they are managed very differently from pre-transplant HE: [1]
Early (0-30 days post-transplant)
Drug / procedural
- Lingering pre-transplant encephalopathy — clears over days to weeks as ammonia disposal recovers
- Calcineurin-inhibitor neurotoxicity (tacrolimus or cyclosporin) — PRES pattern (occipital/parietal vasogenic oedema on MRI), tremor, headache, seizures
- Peri-operative stroke or intracranial haemorrhage (coagulopathy + reperfusion)
- Opportunistic CNS infection under intense induction immunosuppression (CMV, EBV-PTLD, cryptococcus, toxoplasmosis, Listeria)
- Osmotic demyelination (central pontine myelinolysis) if sodium correction was too rapid peri-operatively
Calcineurin-inhibitor neurotoxicity
Common and reversible
- PRES (posterior reversible encephalopathy syndrome) — classic MRI: bilateral vasogenic oedema in occipital and parietal regions
- Management: dose reduction, or switch tacrolimus to belatacept or cyclosporin (cross-toxicity is partial)
- Usually fully reversible once the offending drug is reduced or switched
- Differentiate from pre-transplant HE — PRES has occipital predominance and may include seizures/visual symptoms
Late / persistent
Often under-recognised
- Persistent cognitive impairment in up to 50% of patients at 1 year, even with excellent graft function — partly reflects pre-transplant brain injury
- Chronic immunosuppression neurotoxicity — fine tremor, mood and cognition effects
- Recurrent HE is rare post-transplant — if it occurs, suspect graft dysfunction or a new portosystemic shunt
- Rehabilitation and cognitive therapy improve functional outcomes
Acute liver failure (ALF) — a different entity
Acute liver failure (ALF)
No pre-existing liver disease
- Onset of encephalopathy within 26 weeks of liver injury
- Causes: paracetamol (#1 in West), viral hepatitis, drug-induced, Wilson disease
- Risk of cerebral oedema and raised ICP (especially Grade III-IV)
- Coagulopathy (INR >1.5 is part of definition)
- Risk of multi-organ failure: AKI, ARDS, sepsis, hypoglycaemia
- Mortality 30-50% without transplant; transplant changes prognosis
- Urgent transplant assessment using King College Criteria
Acute-on-chronic liver failure (ACLF)
Decompensation on cirrhosis
- Acute decompensation of known cirrhosis
- Organ failure: liver, kidney, brain, coagulation, circulation, lung
- EASL and CLIF-C criteria for diagnosis and prognosis
- Precipitants: infection, GI bleed, alcohol, drugs
- 28-day mortality 30-50% depending on number of organ failures
- Treatment: manage precipitant + organ support ± transplant
ALF management priorities
Acute liver failure ICU management
Airway protection
Intubate if Grade III-IV HE (GCS <8 or rapidly deteriorating). Airway protection prevents aspiration pneumonia which is rapidly fatal in ALF.
N-acetylcysteine (NAC)
Give NAC to ALL ALF patients (not just paracetamol). Lee et al (2009): NAC improved transplant-free survival in non-acetaminophen ALF. Dose: 150 mg/kg loading over 1h, then 50 mg/kg over 4h, then 100 mg/kg over 16h. Low risk, potential benefit.
Cerebral oedema and ICP management
Grade III-IV ALF = high risk of intracranial hypertension. Consider ICP monitor. Manage per Seattle algorithm (see Raised ICP topic): head elevation 30 degrees, normocapnia, hyperosmolar therapy (3% NaCl), avoid hypotension/hypoxia. Hypothermia NOT recommended.
Coagulopathy
INR is a marker of liver synthetic function — do NOT routinely correct with FFP unless actively bleeding or before procedures. Give vitamin K 10 mg IV. Platelets >50 for invasive procedures. Recombinant factor VIIa for emergencies.
Hypoglycaemia
Check glucose hourly. Maintain glucose >4 mmol/L with 10% dextrose infusion. Impaired gluconeogenesis from liver failure. Hypoglycaemia worsens brain injury.
Renal support
AKI common (hepatorenal syndrome or ATN). Avoid nephrotoxins. CRRT if indicated. Continuous preferred over intermittent (avoid haemodynamic instability and rapid solute shifts that could worsen cerebral oedema).
Infection surveillance
High infection risk (impaired immunity). Surveillance cultures. Empirical antibiotics if clinical deterioration (infection precipitates multi-organ failure). Antifungal cover if prolonged ICU stay.
Liver transplant assessment
Urgent referral to transplant centre. Use King College Criteria to determine transplant listing. Time is critical — brain death from cerebral oedema is the #1 cause of death in ALF.
King's College Criteria for liver transplant in ALF
[1] [1]Prognosis
Hepatic encephalopathy and ALF outcomes
Exam practice
SAQ — Hepatic encephalopathy
10 minutes · 10 marks
A 58-year-old man with known alcoholic cirrhosis is admitted to ICU with confusion and drowsiness. GCS 12 (E3V3M6). He has ascites and asterixis. Temperature 38.3C, HR 105, BP 100/60. Na 128, K 3.1, creatinine 145, INR 2.1. Ascitic fluid: 350 neutrophils/mm3. Blood cultures pending.
SAQ — Grade III-IV hepatic encephalopathy in the intubated cirrhotic
10 minutes · 10 marks
A 62-year-old man with alcohol-related cirrhosis (Child-Pugh C, MELD-Na 26) is admitted with worsening drowsiness over 24 hours. On examination he is somnolent, responds only to pain, GCS 7 (E1V2M4), with marked asterixis when roused, ascites and bilateral wheeze. Temperature 37.1C, HR 96, BP 105/65, lactate 2.8. Na 131, K 3.2, creatinine 130, INR 2.4, ammonia 145 umol/L. He requires intubation for airway protection. He has been on lactulose 30 mL TDS as an outpatient with poor adherence.
SAQ — Hepatic encephalopathy precipitated by sepsis and spontaneous bacterial peritonitis
10 minutes · 10 marks
A 55-year-old woman with hepatitis-C cirrhosis and ascites is brought in with 2 days of worsening confusion and fever. GCS 11 (E3V3M5), temperature 38.6C, HR 118, BP 88/52, lactate 4.2. She has abdominal tenderness and asterixis. Na 129, K 3.4, creatinine 165, INR 2.2, bilirubin 85, albumin 24. Ascitic tap shows 620 neutrophils/mm3. She meets qSOFA 3 and lactate criteria for septic shock.
Clinical pearls
Red flags
[1]References
- [1]Aldridge DR, Tranah EJ, Shawcross DL. Clinical Manifestations of Hepatic Encephalopathy Clin Liver Dis, 2020.PMID 32245526
- [2]Hadihambi A, Rose CF, Bhatt DL, et al. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy J Hepatol, 2020.PMID 33097308
- [3]Bajaj JS, Kamath PS, Reddy KR, et al. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis Cochrane Database Syst Rev, 2023.PMID 37467180
- [4]Sarwar A, Sattar A, Sattar M, et al. Beyond Lactulose: Treatment Options for Hepatic Encephalopathy Gastroenterol Nurs, 2019.PMID 31145253
- [5]Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure Gastroenterology, 2009.PMID 19524577
- [6]EASL Clinical Practice Guidelines. EASL Clinical Practice Guidelines on acute-on-chronic liver failure J Hepatol, 2023.PMID 37364789
- [7]Sarin SK, Choudhury AK, Sharma MK, et al. Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia Hepatol Int, 2025.PMID 39961976
- [8]Bass NM, Mullen KD, Sanyal A, et al. Eicosanoid actions in insect immunity J Innate Immun, 2009.PMID 20375586